J&J Psoriasis Drug Might Pose Risk: FDA Staff

Law360, New York (June 16, 2008, 12:00 AM ET) -- Medical review staff at the U.S. Food and Drug Administration have raised the possibility that long-term use of ustekinumab, an experimental treatment for psoriasis from Johnson & Johnson, could increase the risk of cancer.

In documents prepared for a meeting of the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on Tuesday, June 17, the FDA staff said that there were no clinical studies showing a correlation between long-term ustekinumab treatment and cancer, but that “[d]ue to the mechanism of action of ustekinumab ... there is a...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required